Puma Biotechnology, Inc.
NASDAQ:PBYI
2.95 (USD) • At close November 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Puma Biotechnology, Inc. |
Symbool | PBYI |
Munteenheid | USD |
Prijs | 2.95 |
Beurswaarde | 144,687,765 |
Dividendpercentage | 0% |
52-weken bereik | 2.23 - 7.73 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Alan H. Auerbach |
Website | https://www.pumabiotechnology.com |
An error occurred while fetching data.
Over Puma Biotechnology, Inc.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)